Literature DB >> 1609177

The use of subjective rankings in clinical trials with an application to cardiovascular disease.

D Follmann1, J Wittes, J A Cutler.   

Abstract

Evaluating a clinical trial can be problematic if the studied treatments affect patients in many ways. A possible method for evaluating treatments is to have raters rank all the patients' trial experiences and then test whether the distribution of ranks differ between treatments. Before one can advocate such a procedure, however, one would like to be assured that raters agree fairly well with one another. As a first step in examining whether raters tend to agree, we conducted a small study with 20 raters evaluating 43 trial experiences from an imaginary cardiovascular clinical trial. Raters showed a high degree of consensus. Moreover, the average ranks agreed fairly well with two quantitative ranking rules. On the other hand, the average ranks did not agree very well with weightings usually selected in cardiovascular trials. These results suggest ranking may be a feasible approach to analysing certain clinical trials with multiple outcomes.

Entities:  

Mesh:

Year:  1992        PMID: 1609177     DOI: 10.1002/sim.4780110402

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  A hierarchical rank test for crossover trials with censored data.

Authors:  Erica Brittain; Dean Follmann
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

3.  Defining Study Outcomes That Better Reflect Individual Response to Treatment.

Authors:  Konstantia Angelidou; Paul Palumbo; Jane Lindsey; Avy Violary; Moherndran Archary; Linda Barlow; Brian Claggett; Michael Hughes; Lee-Jen Wei
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

4.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

5.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

6.  Rethinking composite end points in clinical trials: insights from patients and trialists.

Authors:  Joshua M Stolker; John A Spertus; David J Cohen; Philip G Jones; Kaushik K Jain; Emily Bamberger; Brady B Lonergan; Paul S Chan
Journal:  Circulation       Date:  2014-09-08       Impact factor: 29.690

7.  Evaluation of efficacy and biocompatibility of a novel semisynthetic collagen matrix as a dural onlay graft in a large animal model.

Authors:  Axel Neulen; Angelika Gutenberg; Ildikó Takács; György Wéber; Jürgen Wegmann; Walter Schulz-Schaeffer; Alf Giese
Journal:  Acta Neurochir (Wien)       Date:  2011-07-09       Impact factor: 2.216

8.  Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis.

Authors:  Grace Montepiedra; Courtney M Yuen; Michael L Rich; Scott R Evans
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-08

9.  A patient-centered composite endpoint weighting technique for orthopaedic trauma research.

Authors:  Ugochukwu N Udogwu; Andrea Howe; Katherine Frey; Marckenley Isaac; Daniel Connelly; Dimitrius Marinos; Mitchell Baker; Renan C Castillo; Gerard P Slobogean; Robert V O'Toole; Nathan N O'Hara
Journal:  BMC Med Res Methodol       Date:  2019-12-26       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.